Short-term fasting during chemotherapy – Investigation of tumor cells in the blood
Résumé de l'étude
This study investigates how short fasting around the first chemotherapy affects cancer cells that can be detected in the blood. These cells are called circulating tumor cells. They can enter the bloodstream from the tumor and may be related to the course of the disease. Adult female patients with breast cancer or a gynecological cancer who receive chemotherapy as standard treatment can participate. The chemotherapy itself will not be altered by participation in the study. Some participants will fast under medical supervision for about 36–40 hours around the first chemotherapy. Other participants will not fast and will receive chemotherapy as usual. This allows for comparison of whether circulating tumor cells change differently in patients with and without fasting. During the study, blood samples will be taken at specified times. This will allow for the examination of circulating tumor cells and additional measurements related to metabolism. Some blood samples will be taken at specific times of the day to account for natural daily fluctuations. No additional examinations such as CT or MRI will be conducted. Participation lasts only a few days around the first chemotherapy. Fasting will be medically supervised and can be stopped at any time if a participant feels unwell. No direct personal benefit is expected. The results are intended to help better understand the relationship between fasting, metabolism, and circulating tumor cells during chemotherapy, thereby creating a foundation for further research. Participation is voluntary; non-participation or withdrawal will not have disadvantages for further treatment.
(BASEC)
Intervention étudiée
Short-term, medically supervised fasting around the first chemotherapy.
The intervention consists of a time-limited abstention from calorie intake for about 36–40 hours in the peri-chemotherapeutic period. No medication or medical product is used. Chemotherapy is carried out independently of the study according to medical standards and is not altered by the intervention.
(BASEC)
Maladie en cours d'investigation
Metastatic breast cancer and metastatic gynecological cancers
(BASEC)
1. Adult female patients (≥ 18 years) with histologically confirmed metastatic breast cancer or metastatic gynecological cancers. 2. Planned systemic chemotherapy according to medical standards at the University Hospital Basel. 3. Ability to understand the study procedures and provide written consent to participate in the study. (BASEC)
Critères d'exclusion
1. Medical conditions that contraindicate short-term fasting, particularly uncontrolled diabetes mellitus, eating disorders, or clinically relevant malnutrition. 2. Severe comorbidities that, in the opinion of the investigator, do not allow for safe participation in the study. 3. Pregnancy or breastfeeding. (BASEC)
Lieu de l’étude
Bâle
(BASEC)
Sponsor
Universitätsspital Basel
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Prof. Dr. Viola Heinzelmann-Schwarz
+41 61 265 25 25
viola.heinzelmann@clutterusb.chUniversitätsspital Basel, Frauenklinik / Gynäkologische Onkologie
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Date d'approbation du comité d'éthique
29.05.2026
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
Fasting and Circulating Tumor Cells (CTCs) in Metastatic Breast and Gynecologic Cancers: A Pilot Study on Short-Term Fasting and CTC Dynamics (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible